Bristol-Myers Squibb Co.

RSS Feed
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company's products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. The company manufactures products in the United States and Puerto Rico and has manufacturing operations in two foreign countries. The company has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. The company's pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.
  • TickerBMY
  • ISINUS1101221083
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
TheScreener

BRISTOL MYERS SQUIBB sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of BRISTOL MYERS SQUIBB (US), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date March 19, 2021, the closing price was USD 62.70 and its potential was estimated at USD 69.19.

EUR 12.54
Quant
Health Care
Bristol-Myers Squibb Co.
25d 20/03/2021 6 EN
Moody's Investors Service

Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

EUR 627.00
Fixed Income
Health Care
Bristol-Myers Squibb Co.
26d 18/03/2021 1 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

EUR 41.80
Equity
Chemicals
APD , LNT ...
61d 11/02/2021 1 EN
Moody's Investors Service

Bristol-Myers Squibb Company: Update to credit analysis following outlook revision to stable from negative

Our credit view of Bristol-Myers Squibb, reflecting its good global scale, moderate financial leverage and strong free cash flow, tempered by revenue concentration in several core products.

EUR 209.00
Fixed Income
Health Care
Bristol-Myers Squibb Co.
67d 05/02/2021 11 EN
Moody's Investors Service

Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company. Global Credit Research- 15 Dec 2020. New York, December 15, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with the same analytical unit.

Fixed Income
Health Care
Bristol-Myers Squibb Co.
119d 15/12/2020 4 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-t...

EUR 209.00
Chart
Technology
ACMR , ADTN ...
351d 28/04/2020 55 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Technology
VNET , ACAD ...
355d 24/04/2020 42 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

EUR 41.80
Chart
Technology
AMD , ACM ...
1y 13/01/2020 25 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Small-Caps Closing the Gap Major averages in the US (S&P 500, Dow, Russell 2000) and Europe (STOXX 600 & 50) each had throwbacks to their prior breakout levels last week, with all making successful tests of support amid reports of a potential setback in trade negotiations... see charts below. Thus far, buy-the-dippers have been rewarded. While a retest of these lows is possible -- particularly if something goes awry regarding US-China trade or the Fed -- we continue to believe dips should be bought as the weight of the evidence continues to point to a new leg higher for the broad equity marke...

EUR 209.00
Chart
Health Care
ABBV , ACIU ...
1y 12/12/2019 35 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Many Consumer Discretionary names are staging reversals or developing bullish bases. (ex. CPRI, CRI, OXM, PENN, LOCO, PZZA, DPZ, WW, CHS, ZUMZ, and GES) • The Healthcare Sector has a significant number of names reversing downtrend, breaking out of bases, and in uptrends (ex. CAH, TCMD, THC, SEM, MGLN, RGEN, REGN, MEDP, PRAH, and BMY) • Semis and Semi suppliers continue to develop positively. (ex. UCTT, ICHR, FORM, AEIS, and BRKS)

EUR 41.80
Chart
Technology
AEIS , ACM ...
1y 07/12/2019 23 EN
SmartInsider

Bristol Myers Squibb Co: 3 directors sold

Three Directors at Bristol Myers Squibb Co sold 34,321 shares at between 61.340USD and 63.390USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under li...

EUR 8.36
Corporate Voice
Health Care
Bristol-Myers Squibb Co.
139d 26/11/2020 1 EN
BusinessWire

Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise

NEW YORK--(BUSINESS WIRE)-- (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. “We are excited to welcome MyoKardia colleagues to Bristol Myers Squibb. The MyoKardia team has revolutionized cardiovascular treatments to address significant unmet medical needs, and we look forward to helping more patients tog...

Free
Corporate Voice
Health Care
Bristol-Myers Squibb Co.
148d 17/11/2020 1 EN
BusinessWire

Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion. The expiration of the waiting period occurred at 11:59 p.m. EST on November 3, 2020. This press release features multimedia. View the full release her...

Free
Corporate Voice
Health Care
Bristol-Myers Squibb Co.
161d 04/11/2020 1 EN
BusinessWire

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020. MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Through the transaction, B...

Free
Corporate Voice
Health Care
Bristol-Myers Squibb Co.
191d 05/10/2020 1 EN
BusinessWire

European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated a type II variation application for the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for treatment in adult patients with first-line metastatic non-small cell lung cancer (NSCLC) who have tumor mutational burden (TMB) ≥10 mutations/megabase (mut/Mb). Validation of the application confirms the submission is complete and begins the EMA’s centralized review process. ...

Free
Corporate Voice
Health Care
Bristol-Myers Squibb Co.
3y 03/05/2018 1 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

EUR 41.80
Equity
Chemicals
APD , LNT ...
61d 11/02/2021 1 EN
MarketLine
MarketLine Department

Celgene Corporation - Strategy, SWOT and Corporate Finance Report

Summary Celgene Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Celgene Corporation (Celgene or 'the company') is a biopharmaceutical company that produces and sells novel therapies for the treatment of inflammatory diseases and cancer through next-generation solutions in immuno-oncology, protein homeostasis, immunology, epigenetics and neuro-inflamm...

EUR 146.30
Equity
Health Care
AMGN , BIIB ...
135d 29/11/2020 66 EN
MarketLine
MarketLine Department

Allergan plc - Strategy, SWOT and Corporate Finance Report

Summary Allergan plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Allergan plc (Allergan or 'the company') is a pharmaceutical company that develops, manufactures and markets branded pharmaceutical products, biologic, device, surgical and regenerative medicine products. The company offers products in various therapeutic areas, including central nervous system...

EUR 146.30
Equity
Retail
ABC , BMY ...
135d 29/11/2020 68 EN
MarketLine
MarketLine Department

Johnson & Johnson - Strategy, SWOT and Corporate Finance Report

Summary Johnson & Johnson - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Johnson & Johnson (J&J or 'the company') is a health care company that develops, manufactures and markets consumer health care products, pharmaceuticals and medical devices. It offers pharmaceuticals in the therapeutic areas of immunology, oncology, neuroscience, infectious diseases and va...

EUR 146.30
Equity
Health Care
ABT , BEI ...
135d 29/11/2020 73 EN
MarketLine
MarketLine Department

AbbVie Inc. - Strategy, SWOT and Corporate Finance Report

Summary AbbVie Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights AbbVie Inc. (AbbVie or 'the company') is a biopharmaceutical company that discovers, develops, manufactures and commercializes drugs for the treatment of chronic and complex diseases. The company develops pharmaceutical products that mainly consist of Humira (adalimumab) and products in therapeu...

EUR 146.30
Equity
Health Care
AMGN , BMY ...
135d 29/11/2020 67 EN
Moody's Investors Service

Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

EUR 627.00
Fixed Income
Health Care
Bristol-Myers Squibb Co.
26d 18/03/2021 1 EN
Moody's Investors Service

Bristol-Myers Squibb Company: Update to credit analysis following outlook revision to stable from negative

Our credit view of Bristol-Myers Squibb, reflecting its good global scale, moderate financial leverage and strong free cash flow, tempered by revenue concentration in several core products.

EUR 209.00
Fixed Income
Health Care
Bristol-Myers Squibb Co.
67d 05/02/2021 11 EN
Moody's Investors Service

Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company. Global Credit Research- 15 Dec 2020. New York, December 15, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with the same analytical unit.

Fixed Income
Health Care
Bristol-Myers Squibb Co.
119d 15/12/2020 4 EN
Moody's Investors Service

Bristol-Myers Squibb Company - September 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

EUR 627.00
Fixed Income
Health Care
Bristol-Myers Squibb Co.
134d 01/12/2020 1 EN
Moody's Investors Service

Moody's assigns A2 to Bristol-Myers' sr. notes; outlook negative

Rating Action: Moody's assigns A2 to Bristol-Myers' sr. notes; outlook negative. Global Credit Research- 09 Nov 2020. New York, November 09, 2020-- Moody's Investors Service assigned an A2 rating to the new senior unsecured notes of Bristol-Myers Squibb Company.

EUR 150.48
Fixed Income
Health Care
Bristol-Myers Squibb Co.
155d 09/11/2020 5 EN
TheScreener

BRISTOL MYERS SQUIBB sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of BRISTOL MYERS SQUIBB (US), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date March 19, 2021, the closing price was USD 62.70 and its potential was estimated at USD 69.19.

EUR 12.54
Quant
Health Care
Bristol-Myers Squibb Co.
25d 20/03/2021 6 EN
Ford Equity Research

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

EUR 18.48
Quant
Health Care
Bristol-Myers Squibb Co.
4y 23/12/2016 3 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch